Literature DB >> 11087205

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

J MacLennan1, S Obaro, J Deeks, D Lake, C Elie, G Carlone, E R Moxon, B Greenwood.   

Abstract

Infant vaccination with meningococcal conjugates may provide long-term protection against disease. Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy. At 2 years, they were randomized to receive a booster of MenA/C (conjugate group), meningococcal A/C polysaccharide (MPS group), or inactivated polio vaccine (IPV group). All groups were revaccinated with 10 microg MPS at 5 years of age, as were 39 previously unvaccinated age-matched control subjects. Before revaccination, titers were higher in the conjugate and MPS groups than in control subjects (P<.001); titers for the IPV group were similar to those for control subjects. Ten days after revaccination, the conjugate and IPV groups had similar serogroup C serum bactericidal antibody titers (3421 vs. 2790, respectively). These levels were significantly higher than those in the MPS (426) and control (485) groups (P<.001). Thus, immunologic memory was sustained for > or =5 years; however, MPS challenge at 2 years interfered with a subsequent memory response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087205     DOI: 10.1086/317667

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.

Authors:  Helen Findlow; Jo Southern; Lesley Mabey; Paul Balmer; Robert S Heyderman; Cressida Auckland; Rhonwen Morris; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2006-04

Review 4.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

Review 5.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 6.  Regulation of capsule in Neisseria meningitidis.

Authors:  Yih-Ling Tzeng; Jennifer Thomas; David S Stephens
Journal:  Crit Rev Microbiol       Date:  2015-06-19       Impact factor: 7.624

7.  Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.

Authors:  Markus A Rose; Ralf Schubert; Nicola Strnad; Stefan Zielen
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.

Authors:  Tamara Menéndez; Tania Carmenate; Yoelys Cruz-Leal; Edelgis Coizeau; Evelyn Caballero; Daniel Bello; María Guirola; Anabel Alvarez; Gerardo Guillén
Journal:  Curr Microbiol       Date:  2009-09-23       Impact factor: 2.188

10.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.